Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Phase I Research of Extended-Release Topiramate Shows Less Fluctuation in Plasma Levels

April 11, 2011 By Bio-Medicine.Org

MAPLE GROVE, Minn., April 11, 2011 /PRNewswire/ — Upsher-Smith
Laboratories today announced the presentation of data indicating
that once daily administration of USL255, a proprietary
extended-release (ER) formulation of the epilepsy medication
topiramate, was associated with less fluctuation in topiramate
plasma levels compared to immediate-release (IR) topiramate
administered twice daily in healthy volunteers.

These data were presented Monday, April 11 at the American
Academy of Neurology’s (AAN) 2011 Annual Meeting in Honolulu, HI,
and marked another milestone in Upsher-Smith’s commitment to
addressing unmet patient needs in epilepsy and other central
nervous system diseases.

USL255 is being developed for the treatment of adults with
partial-onset seizures and is the subject of a Phase III clinical
trial (PREVAIL). This proprietary extended-release formulation is
designed to provide convenient once-daily dosing with reduced
fluctuation in topiramate plasma levels versus traditional IR
dosage forms.

“Fluctuations in plasma levels with certain antiepileptic drugs
have the potential to cause challenges for patients with epilepsy.
There is concern that some individuals may experience increased
side effects during peak concentrations, or suffer break-through
seizures if plasma levels fall too low. We are excited to share
this Phase I data about USL255 and its encouraging pharmacokinetic
profile with clinicians at AAN,” said Mark Halvorsen, Pharm.D.,
Senior Director, Clinical Development at Upsher-Smith.

Abstracts of the poster presentations can be found online at www.aan.com. Titles and authors
are:

  • “Development and Optimization of Extended-Release Formulations
    of Topiramate.” Authors: Lawrence J. Lambrecht, Wesley M. Todd,
    John A. Carrithers, Mark B. Halvorsen.
  • “Pharmacokinetic Equivalence Between Immediate-Release
    Topiramate and USL255 (A Novel

    ‘/>”/>

SOURCE

Related Articles Read More >

DeepWell Digital Therapeutics Mike Wilson Ryan Douglas
How DeepWell is developing video games as tools for treating medical conditions
A woman with a small, handheld device in her lap with tubes that look like earphones plugged into her ears.
Ear-puffing device for migraine treatment wins FDA breakthrough designation
Abbott
Abbott launches upgraded digital health app for neurostimulation
Catheter delivery could enable better brain implants: Synchron’s neuroscience chief explains how

DeviceTalks Weekly.

June 24, 2022
How innovative design, commercial strategy is building Cala Trio’s bioelectronic medicine market
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech